Metaphore Biotechnologies
Series D
Metaphore Biotechnologies: Unveiling revolutionary therapies through biomimicry and machine learning.
Founded
2021Metaphore Biotechnologies: Unveiling revolutionary therapies through biomimicry and machine learning.
Metaphore Biotechnologies, founded with a mission to revolutionize medicine through biomimicry and machine learning, focuses on developing novel therapies using its proprietary MIMiCTM platform. This computationally driven bio platform is designed to optimize function, specificity, and selectivity in therapeutic development. The company's vision is to uncover previously inaccessible pharmacological targets, aiming for breakthroughs that surpass current medications for maximum patient impact.
Notable affiliated individuals and investors include leading experts in biotechnology and computational biology, although specific names are not provided. Key achievements of Metaphore Biotechnologies include the successful development and application of the MIMiCTM platform, positioning the company at the forefront of innovative therapeutic solutions. The overall impact of Metaphore Biotechnologies lies in its potential to transform the landscape of drug discovery and development, offering new hope for treatments that were previously unattainable.
Companies similar to Metaphore Biotechnologies include Metis Therapeutics, Generate Biomedicines, Metanovas Biotech and Mimetics.
Metaphore Biotechnologies was founded in 2021.
Metaphore Biotechnologies' headquarters is located in Cambridge, MA, US.
Metaphore Biotechnologies' most recent funding round was for $50M (USD) in May 2023.
As of May 16, 2023, Metaphore Biotechnologies has raised a total of $50M (USD).
Metaphore Biotechnologies has 30 employees as of Feb 4, 2024.
Metanovas Biotech
metanovas.com
